ir.checkpointtx.comOverview | Checkpoint Therapeutics

Overview Stock Information Press Releases Corporate Presentation SEC Filings and Financials SEC Filings Events Management Team Corporate Governance Analyst Coverage FAQs Information Request Home About Us Management Team Board of Directors Pipeline CK-101 EGFR Inhibitor CK-301 Anti-PD-L1 CK-103 BET Inhibitor CK-302 Anti-GITR Anti-CAIX Publications Business Development Investors & Media Overview Stock Information Press Releases Corporate Presentation SEC Filings and Financials SEC Filings Events Management Team Corporate Governance Analyst Coverage FAQs Information Request Contact Us Investors -- Overview -- -- Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potentially differentiated anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts intended to support one or more Biologics License Application submissions. In addition, Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, in a Phase 1 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (“NSCLC”). Checkpoint is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). Press Releases View All Contact Information Checkpoint Therapeutics, Inc. 2 Gansevoort Street 9th Floor New York, NY 10014 Investor Relations Contact ir@checkpointtx.com Join Our Mailing List Copyright , © Powered By Q4 Inc. 2 Gansevoort Street 9th Floor New York, NY 10014 781-652-4500 info@checkpointtx.com © Copyright 2020 Checkpoint Therapeutics, Inc. Privacy Policy Disclaimer Sitemap REQUEST A MEETING WITH MANAGEMENT...